Dana Pizzuti is Chief Med and Dev Officer of Crinetics Pharmaceuticals, Inc.. Currently has a direct ownership of 27,786 shares of CRNX, which is worth approximately $1.25 Million. The most recent transaction as insider was on Jun 24, 2024, when has been sold 9,500 shares (Common Stock) at a price of $45.73 per share, resulting in proceeds of $434,434. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 27.8K
0% 3M change
517.47% 12M change
Total Value Held $1.25 Million

Dana Pizzuti Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 24 2024
SELL
Open market or private sale
$434,434 $45.73 p/Share
9,500 Reduced 25.48%
27,786 Common Stock
Jun 24 2024
BUY
Exercise of conversion of derivative security
$160,455 $16.89 p/Share
9,500 Added 20.31%
37,286 Common Stock
Apr 15 2024
SELL
Open market or private sale
$639,256 $44.47 p/Share
14,375 Reduced 34.1%
27,786 Common Stock
Apr 15 2024
BUY
Exercise of conversion of derivative security
$242,793 $16.89 p/Share
14,375 Added 25.43%
42,161 Common Stock
Mar 20 2024
SELL
Open market or private sale
$668,291 $44.29 p/Share
15,089 Reduced 35.19%
27,786 Common Stock
Mar 20 2024
BUY
Exercise of conversion of derivative security
$242,793 $16.89 p/Share
14,375 Added 27.19%
38,500 Common Stock
Mar 18 2024
SELL
Payment of exercise price or tax liability
$15,675 $38.14 p/Share
411 Reduced 1.42%
28,500 Common Stock
Mar 04 2024
BUY
Grant, award, or other acquisition
-
23,000 Added 44.31%
28,911 Common Stock
Jan 03 2024
SELL
Open market or private sale
$503,125 $35.0 p/Share
14,375 Reduced 70.86%
5,911 Common Stock
Jan 03 2024
BUY
Exercise of conversion of derivative security
$242,793 $16.89 p/Share
14,375 Added 41.47%
20,286 Common Stock
Dec 21 2023
SELL
Open market or private sale
$331,284 $34.57 p/Share
9,583 Reduced 61.85%
5,911 Common Stock
Dec 21 2023
BUY
Exercise of conversion of derivative security
$161,856 $16.89 p/Share
9,583 Added 38.21%
15,494 Common Stock
Apr 05 2023
SELL
Open market or private sale
$132,623 $16.15 p/Share
8,212 Reduced 64.6%
4,500 Common Stock
Apr 03 2023
SELL
Payment of exercise price or tax liability
$68,522 $15.98 p/Share
4,288 Reduced 25.22%
12,712 Common Stock
Mar 01 2023
BUY
Grant, award, or other acquisition
-
4,500 Added 20.93%
17,000 Common Stock
Oct 10 2022
BUY
Grant, award, or other acquisition
-
12,500 Added 50.0%
12,500 Common Stock
DP

Dana Pizzuti

Chief Med and Dev Officer
San Diego, CA

Track Institutional and Insider Activities on CRNX

Follow Crinetics Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CRNX shares.

Notify only if

Insider Trading

Get notified when an Crinetics Pharmaceuticals, Inc. insider buys or sells CRNX shares.

Notify only if

News

Receive news related to Crinetics Pharmaceuticals, Inc.

Track Activities on CRNX